<DOC>
	<DOCNO>NCT01576042</DOCNO>
	<brief_summary>The purpose pilot trial determine feasibility large , multi-center randomized clinical trial aim test whether treatment strategy percutaneous catheter ablation ventricular tachycardia ( VT ) superior state-of-the-art pharmacologic therapy reduce all-cause mortality patient implantable cardioverter defibrillator ( ICD ) receive therapy VT absence reversible cause .</brief_summary>
	<brief_title>Pilot Study Catheter Ablation Ventricular Tachycardia Patients With Implantable Cardioverter Defibrillator</brief_title>
	<detailed_description>This study conduct 8 site randomize 50 patient 1 year strategy catheter ablation ( n=25 ) vs. state-of-the-art pharmacologic therapy ( n=25 ) . To consider enrollment pilot trial , patient must least 18 year age must ICD primary secondary prevention indication , ≥ 1 documented ICD shock ≥ 3 ATP therapy VT absence reversible cause opinion treat physician require therapy eligible catheter ablation least 1 antiarrhythmic medication . Patients follow 3 6 month vital status determine via phone call 12 month . Data safety efficacy therapy use pilot study collect . Of particular interest adverse event result catheter ablation procedure major side effect antiarrhythmic medication .</detailed_description>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<mesh_term>Sotalol</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<criteria>Have ICD without cardiac resynchronization therapy ( i.e . CRTD ) primary secondary prevention indication Have ischemic heart disease define presence wall motion abnormality document coronary artery disease ( one ≥ 70 % stenosis ≥ 1 major coronary artery ) Have ≥ 1 documented ICD shock ≥ 3 ATP therapy within 6 month randomization VT absence reversible cause opinion treat physician require therapy . The VT monomorphic rate ≤ 260 bpm . Be least 18 year age Be eligible catheter ablation Have history intolerance contraindication least 1 follow antiarrhythmic medication : amiodarone , sotalol , mexiletine . Exclusion : Patients opinion treat physician receive additional therapy More 30 day amiodarone treatment past 3 month unless patient ≤ 200 mg amiodarone daily atrial arrhythmia premature ventricular contraction ( PVCs ) patient eligible high dose amiodarone Incessant VT necessitate immediate treatment Reversible cause VT include limited ischemia , decompensated HF , electrolyte disturbances The presence contraindication catheter ablation VT ( include presence mobile ventricular thrombus ; acute MI , coronary revascularization , stroke precede 30 day ; unstable angina NYHA class IV HF ; mechanical valve ; inability receive anticoagulation antithrombotic therapy ) Patients nonischemic cardiomyopathy Patients hypertrophic obstructive , restrictive , infiltrative cardiomyopathy Patients acute myocarditis , congenital heart disease , valvular disease likely require surgery next 1 year , and/or inoperable obstructive valvular disease Patients heart transplant expect undergo cardiac transplantation within 12 month Patients leave ventricular assist device Patients already antiarrhythmic drug therapy ( betablockers ) VT ( patient exclude receive antiarrhythmic drug therapy atrial arrhythmia PVCs eligible additional drug therapy VT ) . Heritable arrhythmia increase risk torsade de pointes class III drug End stage renal disease require dialysis Estimated life expectancy &lt; 1 year noncardiac cause Women pregnant childbearing potential use reliable method contraception Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Ischemic heart disease</keyword>
	<keyword>Implantable Cardioverter Defibrillator</keyword>
	<keyword>Ventricular Tachycardia</keyword>
	<keyword>Patient Implantable Cardioverter Defibrillator ( ICD )</keyword>
</DOC>